API

PO API Capsule | API Pharmaceutical Outsourcing

An active pharmaceutical ingredient (API) is defined in ICH Q7 as “any substance or mixture of substances intended to be used in the manufacture of a drug product and that, when used in the production of a drug, becomes an active ingredient in the drug product. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the body.”

Active pharmaceutical ingredients are distinguishable from inactive pharmaceutical ingredients, commonly known as excipients or formulation aids.

The European Medicines Agency, and the US FDA have adopted the ICH Q7 definition of APIs.

Many other terms are used interchangeably with API. They include:

  • active
  • bulk pharmaceutical chemical
  • drug substance
  • active principle (especially for natural extracts)
  • therapeutic ingredient

Filter

Hide Filter
  • Industry Benchmark

    Wednesday, March 15, 2017
    At the heart of That’s Nice is the Nice Insight division, which provides data and analysis from proprietary annual surveys as well as custom primary and secondary research of many kinds. Nice Insight is tasked every year with conducting a series of ... read more
  • Investing for Successful Advancement of Viral Vector Manufacturing

    Wednesday, March 15, 2017
    Gene therapies are designed to treat diseases by modifying genetic information, including correcting genes that function improperly or adding normal copies of defective genes. They have the potential to address and potentially cure a wide range of ... read more
  • Nice Insight: 2017 Industry Leaders

    Wednesday, March 15, 2017
    Nice Insight conducted seven annual studies to survey the pharma landscape and measure what buyers in the market want. These surveys were deployed to respondents in the diverse and dynamic sectors of CDMO, CRO, Equipment, Intermediate, ... read more
  • Continuous Manufacturing: To Be Continued…

    Wednesday, March 15, 2017
    CONTINUOUS MANUFACTURING OFFERS OBVIOUS ADVANTAGES TO THE PHARMACEUTICAL SECTOR BUT HAS NOT YET EVOLVED INTO A MAJOR ALTERNATIVE TO BATCH. ARE THINGS ABOUT TO CHANGE? read more
  • Designing a Better Single-use Facility

    Wednesday, March 15, 2017
    Although single-use, disposable technologies (SUTs) have been around for decades, continued development and implementation of this innovative process technology is needed to help accelerate the advancement of biopharmaceutical drug development. read more
  • Innovation And Partnership Through Experience And Acquisition

    Wednesday, March 15, 2017
    The pharmaceutical marketplace is more global than ever and, as companies fight for market share in this increasingly competitive landscape, contract development and manufacturing organizations (CDMOs) are becoming more important than ever. read more
  • There Is Almost No Aspect of the Life Sciences and Related Industries That Big Data Cannot Impact.

    Wednesday, March 15, 2017
    It can help in disease pattern analysis by bringing information together in new ways; it facilitates drug discovery by enabling advanced search capabilities for analyzing millions of publications, patents and clinical trial documents; it can also ... read more
  • Growth Anticipated for Intermediates

    Wednesday, March 15, 2017
    Pharmaceutical buyers have much lower budgets when it comes to buying intermediates than excipients or outsourced services, but their needs remain highly diverse in terms of type of product and chemistry. However basic this segment of the ... read more
  • Next-Generation OSD Manufacturing Strategy

    Wednesday, March 15, 2017
    The Facility of the Future has to be more agile, flexible and efficient than it is today. How to get there? By innovating — introducing new processing concepts, analytics and control — and pulling it together with attention to flow and ergonomics... read more
  • Dissolving Boundaries In Worldwide Clinical Trial Logistics for Biological Samples and New Therapies

    Wednesday, March 15, 2017
    Marken is a leading patient-centric supply chain logistics organization with a complete focus on the pharmaceutical and life-sciences industries. Its state-ofthe- art GMP-compliant network includes 10 GMP-compliant depots and 45 worldwide logistic ... read more
  • Enhancing Responsiveness with Embedded Flexibility

    Wednesday, March 15, 2017
    Responsiveness has always been a key expectation for contract manufacturers providing services to the pharmaceutical industry. Today, however, with increased competition, the growing importance of evidence-based medicine, the expanding focus on ... read more
  • The Data Generation

    Wednesday, March 15, 2017
    The first issue of Pharma’s Almanac in 2017 explores the current market landscape and the impact of Big Data and covers a whole host of other topics: read more
  • Spending on Contract Research Services Slowing Down

    Wednesday, March 15, 2017
    The 2017 Nice Insight Clinical Research Organization (CRO) Outsourcing Survey1 includes input from 608 outsourcing-facing pharmaceutical and biotechnology executives. The majority of the respondents are key decision makers; nearly one-third (31%)... read more
  • Stay Tuned: Pharma’s Almanac TV Goes Live

    Wednesday, March 15, 2017
    If you were at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Denver in November, you surely would not have missed the That’s Nice booth. There was a large company team, pop art imagery, the opportunity to stand ... read more
  • Equipment Must Integrate

    Wednesday, March 15, 2017
    Modern pharmaceutical manufacturing equipment and associated analytical instrumentation is the fundamental ‘hardware’ required to produce safe, effective, highquality medicinal products. To meet the challenges from increasingly downward price ... read more